This white paper examines the Philippines’ emerging role in global oncology clinical trials, highlighting its patient population relevance, investigator and site readiness, and growing experience across Phase I–IV studies. Based on survey data and country-level evidence, it provides actionable guidance on feasibility, including biomarker workflows, recruitment dynamics and optimal trial archetypes for sponsors evaluating clinical development in Asia Pacific.